The beneficial effects of Ganoderma lucidum on cardiovascular and metabolic disease risk

References

• Abdullah N, Ismail SM, Aminudin N, Shuib AS, Lau BF. 2012. Evaluation of selected culinary-medicinal mushrooms for antioxidant and ACE inhibitory activities. Evid Based Complement Alternat Med. 2012:464238.
   PubMed Web of Science ®Google Scholar
• Ahmad MF. 2018. Ganoderma lucidum: persuasive biologically active constituents and their health endorsement. Biomed Pharmacother. 107:507–519.
   PubMed Web of Science ®Google Scholar
• Ahmad MF, Ahmad FA, Azad ZAA, Alam MI, Ansari JA, Panda BP. 2013. Edible mushrooms as health promoting agent. Adv Sci Focus. 1(3):189–196.
   Google Scholar
• American Diabetes Association. 2020. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2020. Diabetes Care. 43(Supplement 1):S98–S110.
   PubMed Web of Science ®Google Scholar
• Baby S, Johnson AJ, Govindan B. 2015. Secondary metabolites from Ganoderma. Phytochemistry. 114:66–101.
   PubMed Web of Science ®Google Scholar
• Bach EE, Hi EMB, Martins AMC, Nascimento PAM, Wadt NSY. 2018. Hypoglicemic and hypolipedimic effects of Ganoderma lucidum in streptozotocin-induced diabetic rats. Medicines (Basel). 5(3):78.
   PubMedGoogle Scholar
• Berger A, Rein D, Kratky E, Monnard I, Hajjaj H, Meirim I, Piguet-Welsch C, Hauser J, Mace K, Niederberger P. 2004. Cholesterol-lowering properties of Ganoderma lucidum in vitro, ex vivo, and in hamsters and minipigs. Lipids Health Dis. 3:2.
   PubMedGoogle Scholar
• Bishop KS, Kao CH, Xu Y, Glucina MP, Paterson RR, Ferguson LR. 2015. From 2000 years of Ganoderma lucidum to recent developments in nutraceuticals. Phytochemistry. 114:56–65.
   PubMed Web of Science ®Google Scholar
• Chen DH, Shiou WY, Wang KC, Huang SY, Shie YT, Tsai CM, Shie JF, Chen KD. 1999. Chemotaxonomy of triterpenoid pattern of HPLC of Ganoderma lucidum and Ganoderma tsugae. Jnl Chinese Chemical Soc. 46(1):47–51.
   Web of Science ®Google Scholar
• Chen B, Tian J, Zhang J, Wang K, Liu L, Yang B, Bao L, Liu H. 2017. Triterpenes and meroterpenes from Ganoderma lucidum with inhibitory activity against HMGs reductase, aldose reductase and α-glucosidase. Fitoterapia. 120:6–16.
   PubMed Web of Science ®Google Scholar
• Cherian E, Patani G, Sudheesh NP, Janardhanan KK. 2009. Free-radical scavenging and mitochondrial antioxidant activities of Reishi-Ganoderma lucidum (Curt: Fr) P. Karst and Arogyapacha-Trichopus zeylanicus Gaertn extracts. J Basic Clin Physiol Pharmacol. 20(4):289–308.
   PubMedGoogle Scholar
• Chiu HF, Fu HY, Lu YY, Han YC, Shen YC, Venkatakrishnan K, Golovinskaia O, Wang CK. 2017. Triterpenoids and polysaccharide peptides-enriched Ganoderma lucidum: a randomized, double-blind placebo-controlled crossover study of its antioxidation and hepatoprotective efficacy in healthy volunteers. Pharm Biol. 55(1):1041–1046.
   PubMed Web of Science ®Google Scholar
• Chu TT, Benzie IF, Lam CW, Fok BS, Lee KK, Tomlinson B. 2012. Study of potential cardioprotective effects of Ganoderma lucidum (Lingzhi): results of a controlled human intervention trial. Br J Nutr. 107(7):1017–1027.
   PubMed Web of Science ®Google Scholar
• Curtis W. 1781. Flora Londinensis, or, Plates and descriptions of such plants as grow wild in the environs of London. London: for the author and B. White, [1775]-1777-1798.
   Google Scholar
• Dallmeier D, Larson MG, Vasan RS, Keaney JF, Fontes JD, Meigs JB, Fox CS, Benjamin EJ. 2012. Metabolic syndrome and inflammatory biomarkers: a community-based cross-sectional study at the Framingham Heart Study. Diabetol Metab Syndr. 4(1):28.
   PubMedGoogle Scholar
• Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ, Buse JB. 2018. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 41(12):2669–2701.
   PubMed Web of Science ®Google Scholar
• Dudhgaonkar S, Thyagarajan A, Sliva D. 2009. Suppression of the inflammatory response by triterpenes isolated from the mushroom Ganoderma lucidum. Int Immunopharmacol. 9(11):1272–1280.
   PubMed Web of Science ®Google Scholar
• Eckel RH, Grundy SM, Zimmet PZ. 2005. The metabolic syndrome. Lancet. 365(9468):1415–1428.
   PubMed Web of Science ®Google Scholar
• Endo A. 2004. The origin of the statins. 2004. Atheroscler Suppl. 5(3):125–130.
   PubMed Web of Science ®Google Scholar
• Fatmawati S, Kondo R, Shimizu K. 2013. Structure-activity relationships of lanostane-type triterpenoids from Ganoderma Lingzhi as α-glucosidase inhibitors. Bioorg Med Chem Lett. 23(21):5900–5903.
   PubMed Web of Science ®Google Scholar
• Fatmawati S, Kurashiki K, Takeno S, Kim Y, Shimizu K, Sato M, Imaizumi K, Takahashi K, Kamiya S, Kaneko S, et al. 2009. The inhibitory effect on aldose reductase by an extract of Ganoderma lucidum. Phytother Res. 23(1):28–32.
   PubMed Web of Science ®Google Scholar
• Fatmawati S, Shimizu K, Kondo R. 2010. Ganoderic acid Df, a new triterpenoid with aldose reductase inhibitory activity from the fruiting body of Ganoderma lucidum. Fitoterapia. 81(8):1033–1036.
   PubMed Web of Science ®Google Scholar
• Fatmawati S, Shimizu K, Kondo R. 2011a. Ganoderol B: a potent alpha-glucosidase inhibitor isolated from the fruiting body of Ganoderma lucidum. Phytomedicine. 18(12):1053–1055.
   PubMed Web of Science ®Google Scholar
• Fatmawati S, Shimizu K, Kondo R. 2011b. Structure-activity relationships of ganoderma acids from Ganoderma lucidum as aldose reductase inhibitors. Bioorg Med Chem Lett. 21(24):7295–7297.
   PubMed Web of Science ®Google Scholar
• Ferreira IC, Heleno SA, Reis FS, Stojkovic D, Queiroz MJ, Vasconcelos MH, Sokovic M. 2015. Chemical features of Ganoderma polysaccharides with antioxidant, antitumor and antimicrobial activities. Phytochemistry. 114:38–55.
   PubMed Web of Science ®Google Scholar
• Gao Y, Chen G, Dai X, Ye J, Zhou S. 2004a. A phase I/II study of Ling Zhi mushroom Ganoderma lucidum (W.Curt.:Fr.) Lloyd (Aphyllophoromycetideae) extract in patients with coronary heart disease. Int J Med Mushr. 6(4):327–334.
   Google Scholar
• Gao Y, Lan J, Dai X, Ye J, Zhou S. 2004b. A phase I/II study of Ling Zhi mushroom Ganoderma lucidum (W.Curt.:Fr.) Lloyd (Aphyllophoromycetideae) extract in patients with type II diabetes mellitus. Int J Med Mushrooms. 6(1):33–39.
   Google Scholar
• Giugliano D, Ceriello A, Paolisso G. 1996. Oxidative stress and diabetic vascular complications. Diabetes Care. 19(3):257–267.
   PubMed Web of Science ®Google Scholar
• Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, et al. 2019. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: Executive summary: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation. 139(25):e1046–e1081.
   Google Scholar
• Guarner V, Rubio-Ruiz ME. 2015. Low-grade systemic inflammation connects aging, metabolic syndrome and cardiovascular disease. In: Yashin AI, Jazwinski SM, editors. Aging and health - a systems biology perspective. Basel: Karger; p. 99–106.
   Google Scholar
• Hapuarachchi KK, Wen TC, Jeewon R, Wu XL, Kang JC. 2016. Mycosphere essays 15. Ganoderma lucidum - are the beneficial medical properties substantiated? Mycosphere. 7(6):687–715.
   Web of Science ®Google Scholar
• He CY, Li WD, Guo SX, Lin SQ, Lin ZB. 2006. Effect of polysaccharides from Ganoderma lucidum on streptozotocin-induced diabetic nephropathy in mice. J Asian Nat Prod Res. 8(8):705–711.
   PubMed Web of Science ®Google Scholar
• Hikino H, Ishiyama M, Suzuki Y, Konno C. 1989. Mechanisms of hypoglycemic activity of ganoderan B: a glycan of Ganoderma lucidum fruit bodies. Planta Med. 55(5):423–428.
   PubMedGoogle Scholar
• Hikino H, Konno C, Mirin Y, Hayashi T. 1985. Isolation and hypoglycemic activity of ganoderans A and B, glycans of Ganoderma lucidum fruit Bodies1. Planta Med. 51(4):339–340.
   PubMed Web of Science ®Google Scholar
• Hsu KD, Cheng KC. 2018. From nutraceutical to clinical trial: frontiers in Ganoderma development. Appl Microbiol Biotechnol. 102(21):9037–9051.
   PubMed Web of Science ®Google Scholar
• Hsu PL, Lin YC, Ni H, Mo FE. 2018. Ganoderma triterpenoids exert antiatherogenic effects in mice by alleviating disturbed flow-induced oxidative stress and inflammation. Oxid Med Cell Longev. 2018:3491703.
   PubMed Web of Science ®Google Scholar
• Johansen JS, Harris AK, Rychly DJ, Ergul A. 2005. Oxidative stress and the use of antioxidants in diabetes: linking basic science to clinical practice. Cardiovasc Diabetol. 4:5.
   PubMed Web of Science ®Google Scholar
• Johnson TO, Ermolieff J, Jirousek MR. 2002. Protein tyrosine phosphatase 1B inhibitors for diabetes. Nat Rev Drug Discov. 1(9):696–709.
   PubMed Web of Science ®Google Scholar
• Kanmatsuse K, Kajiwara N, Hayashi K, Shimogaichi S, Fukinbara I, Ishikawa H, Tamura T. 1985. [Studies on Ganoderma lucidum. I. Efficacy against hypertension and side effects]. Yakugaku Zasshi. 105(10):942–947. ].
   PubMed Web of Science ®Google Scholar
• Kao CHJ, Jesuthasan AC, Bishop KS, Glucina MP, Ferguson LR. 2013. Anticancer activities of Ganoderma lucidum: active ingredients and pathways. FFHD. 3(2):48–65.
   Google Scholar
• Kim MY, Seguin P, Ahn JK, Kim JJ, Chun SC, Kim EH, Seo SH, Kang EY, Kim SL, Park YJ, et al. 2008. Phenolic compound concentration and antioxidant activities of edible and medicinal mushrooms from Korea. J Agric Food Chem. 56(16):7265–7270.
   PubMed Web of Science ®Google Scholar
• Kino K, Mizumoto K, Sone T, Yamaji T, Watanabe J, Yamashita A, Yamaoka K, Shimizu K, Ko K, Tsunoo H. 1990. An immunomodulating protein, Ling Zhi-8 (LZ-8) prevents insulitis in non-obese diabetic mice. Diabetologia. 33(12):713–718.
   PubMed Web of Science ®Google Scholar
• Klupp NL, Chang D, Hawke F, Kiat H, Cao H, Grant SJ, Bensoussan A. 2015. Ganoderma lucidum mushroom for the treatment of cardiovascular risk factors. Cochrane Database Syst Rev. 2:CD007259. Art. No.:
   Google Scholar
• Klupp NL, Kiat H, Bensoussan A, Steiner GZ, Chang DH. 2016. A double-blind, randomised, placebo-controlled trial of Ganoderma lucidum for the treatment of cardiovascular risk factors of metabolic syndrome. Sci Rep. 6:29540.
   PubMed Web of Science ®Google Scholar
• Kozarski M, Klaus A, Niksic M, Jakovljevic D, Helsper J, Van Griensven L. 2011. Antioxidative and immunomodulating activities of polysaccharide extracts of the medicinal mushrooms Agaricus bisporus, Agaricus brasiliensis, Ganoderma lucidum and Phellinus linteus. Food Chem. 129(4):1667–1675.
   Web of Science ®Google Scholar
• Kozarski M, Klaus A, Nikšić M, Vrvić MM, Todorović N, Jakovljević D, Van Griensven LJ. 2012. Antioxidative activities and chemical characterization of polysaccharide extracts from the widely used mushrooms Ganoderma applanatum, Ganoderma lucidum, Lentinus edodes and Trametes versicolor. J Food Compost Anal. 26(1–2):144–153.
   Web of Science ®Google Scholar
• Krishna KV, Karuppuraj V, Perumal K. 2016. Antioxidant activity and folic acid content in indigenous isolates of Ganoderma lucidum. Asian Jour Pharmac Anal. 6(4):213–215.
   Google Scholar
• Kumar DP, Koka S, Li C, Rajagopal S. 2019. Inflammatory mediators in obesity. Mediators Inflamm. 2019:9481819.
   PubMed Web of Science ®Google Scholar
• Kumaran S, Palani P, Nishanthi R, Kaviyarasan V. 2011. Studies on screening, isolation and purification of a fibrinolytic protease from an isolate (VK12) of Ganoderma lucidum and evaluation of its antithrombotic activity. Med Mycol J. 52(2):153–162.
   PubMedGoogle Scholar
• Lasukova TV, Maslov LN, Arbuzov AG, Burkova VN, Inisheva LI. 2015. Cardioprotective activity of Ganoderma lucidum extract during total ischemia and reperfusion of isolated heart. Bull Exp Biol Med. 158(6):739–741.
   PubMed Web of Science ®Google Scholar
• Li Z, Liu J, Zhao Y. 2005. Possible mechanism underlying the antiherpetic activity of a proteoglycan isolated from the mycelia of Ganoderma lucidum in vitro. J Biochem Mol Biol. 38(1):34–40.
   PubMedGoogle Scholar
• Li F, Zhang Y, Zhong Z. 2011. Antihyperglycemic effect of Ganoderma lucidum polysaccharides on streptozotocin-induced diabetic mice. Int J Mol Sci. 12(9):6135–6145.
   PubMed Web of Science ®Google Scholar
• Lin JM, Lin CC, Chiu HF, Yang JJ, Lee SG. 1993. Evaluation of the anti-inflammatory and liver-protective effects of Anoectochilus formosanus, Ganoderma lucidum and Gynostemma pentaphyllum in rats. Am J Chin Med. 21(1):59–69.
   PubMed Web of Science ®Google Scholar
• Liperoti R, Vetrano DL, Bernabei R, Onder G. 2017. Herbal medications in cardiovascular medicine. J Am Coll Cardiol. 69(9):1188–1199.
   PubMed Web of Science ®Google Scholar
• Liu C, Huang Y. 2016. Chinese Herbal medicine on cardiovascular diseases and the mechanisms of action. Front Pharmacol. 7:469.
   PubMed Web of Science ®Google Scholar
• Liu F, Ooi VEC, Chang ST. 1997. Free radical scavenging activities of mushroom polysaccharide extracts. Life Sci. 60(10):763–771.
   PubMed Web of Science ®Google Scholar
• Liu Q, Tie L. 2019. Preventive and therapeutic effect of Ganoderma (Lingzhi) on diabetes. Adv Exp Med Biol. 1182:201–215.
   PubMed Web of Science ®Google Scholar
• Liu W, Wang H, Pang X, Yao W, Gao X. 2010. Characterization and antioxidant activity of two low-molecular-weight polysaccharides purified from the fruiting bodies of Ganoderma lucidum. Int J Biol Macromol. 46(4):451–457.
   PubMed Web of Science ®Google Scholar
• Ma H-T, Hsieh J-F, Chen S-T. 2015. Anti-diabetic effects of Ganoderma lucidum. Phytochemistry. 114:109–113.
   PubMed Web of Science ®Google Scholar
• Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, et al. 2020. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 41(1):111–188.
   PubMed Web of Science ®Google Scholar
• Mau JL, Lin HC, Chen CC. 2002. Antioxidant properties of several medicinal mushrooms. J Agric Food Chem. 50(21):6072–6077.
   PubMed Web of Science ®Google Scholar
• McGuffin M, Hobbs C, Upton R, Goldberg A. 1997. American Herbal Products Association’s botanical safety handbook. Boca Raton (FL): CRC Press.
   Google Scholar
• Meng J, Yang B. 2019. Protective effect of Ganoderma (Lingzhi) on cardiovascular system. Adv Exp Med Biol. 1182:181–199.
   PubMed Web of Science ®Google Scholar
• Mohamad Ansor N, Abdullah N, Aminudin N. 2013. Anti-angiotensin converting enzyme (ACE) proteins from mycelia of Ganoderma lucidum (Curtis) P. Karst. BMC Complement Altern Med. 13:256.
   PubMed Web of Science ®Google Scholar
• Pan D, Wang L, Chen C, Hu B, Zhou P. 2015. Isolation and characterization of a hyperbranched proteoglycan from Ganoderma lucidum for anti-diabetes. Carbohydr Polym. 117:106–114.
   Google Scholar
• Pan D, Zhang D, Wu J, Chen C, Xu Z, Yang H, Zhou P. 2013. Antidiabetic, antihyperlipidemic and antioxidant activities of a novel proteoglycan from Ganoderma lucidum fruiting bodies on db/db mice and the possible mechanism. PLoS One. 8(7):e68332.
   PubMed Web of Science ®Google Scholar
• Pan D, Zhang D, Wu J, Chen C, Xu Z, Yang H, Zhou P. 2014. A novel proteoglycan from Ganoderma lucidum fruiting bodies protects kidney function and ameliorates diabetic nephropathy via its antioxidant activity in C57BL/6 db/db mice. Food Chem Toxicol. 63:111–118.
   PubMed Web of Science ®Google Scholar
• Poznyak A, Grechko AV, Poggio P, Myasoedova VA, Alfieri V, Orekhov AN. 2020. The diabetes mellitus-atherosclerosis connection: the role of lipid and glucose metabolism and chronic inflammation. Int J Mol Sci. 21(5):1835.
   PubMed Web of Science ®Google Scholar
• Pravenec M, Kajiya T, Zidek V, Landa V, Mlejnek P, Simakova M, Silhavy J, Malinska H, Oliyarnyk O, Kazdova L, et al. 2011. Effects of human C-reactive protein on pathogenesis of features of the metabolic syndrome. Hypertension. 57(4):731–737.
   PubMed Web of Science ®Google Scholar
• Rahman MA, Abdullah N, Aminudin N. 2018. Evaluation of the antioxidative and hypo-cholesterolemic effects of Lingzhi or Reishi medicinal mushroom, Ganoderma lucidum (Agaricomycetes), in ameliorating cardiovascular disease. Int J Med Mushrooms. 20(10):961–969.
   PubMed Web of Science ®Google Scholar
• Rajasekaran M, Kalaimagal C. 2012. Cardioprotective effect of a medicinal mushroom, Ganoderma lucidum against adriamycin induced toxicity. Int J Pharmacol. 8(4):252–258.
   Google Scholar
• Ratnaningtyas NI, Hernayanti H, Andarwanti S, Ekowati N, Purwanti ES, Sukmawati D. 2018. Effects of Ganoderma lucidum extract on diabetic rats. J Bio Bio Edu. 10(3):642–647.
   Google Scholar
• Rizal A, Sandra F, Fadlan MR, Sargowo D. 2020. Ganoderma lucidum polysaccharide peptide reduce inflammation and oxidative stress in patient with atrial fibrillation. Indones Biomed J. 12(4):384–389.
   Web of Science ®Google Scholar
• Saltarelli R, Ceccaroli P, Iotti M, Zambonelli A, Buffalini M, Casadei L, Vallorani L, Stocchi V. 2009. Biochemical characterisation and antioxidant activity of mycelium of Ganoderma lucidum from Central Italy. Food Chem. 116(1):143–151.
   Web of Science ®Google Scholar
• Sargowo D, Aissy CR, Kalsum U, Nugroho FW, Kamila PA, Irawan D, Sitio M, Adrian LH, Pratama AR, Arifin Y, et al. 2019. The role of polysaccharide peptide of Ganoderma lucidum as a potent protective vascular endothelial cell, anti inflammation, and antioxidant in STEMI and NSTEMI patients. In: Khotimah H, Budianto WY, editors. International conference on bioinformatics and nanomedicine from natural resources for biomedical research. Melville (NY): Amer Inst Physics.
   Google Scholar
• Sarker MMR. 2015. Antihyperglycemic, insulin-sensitivity and anti-hyperlipidemic potential of Ganoderma lucidum, a dietary mushroom, onalloxan-and glucocorticoid-induced diabetic Long-Evans rats. FFHD. 5(12):450–466.
   Google Scholar
• Sarmadi BH, Ismail A. 2010. Antioxidative peptides from food proteins: a review. Peptides. 31(10):1949–1956.
   PubMed Web of Science ®Google Scholar
• Seo HW, Hung TM, Na M, Jung HJ, Kim JC, Choi JS, Kim JH, Lee HK, Lee I, Bae K, et al. 2009. Steroids and triterpenes from the fruit bodies of Ganoderma lucidum and their anti-complement activity. Arch Pharm Res. 32(11):1573–1579.
   PubMed Web of Science ®Google Scholar
• Seto SW, Lam TY, Tam HL, Au AL, Chan SW, Wu JH, Yu PH, Leung GP, Ngai SM, Yeung JH, et al. 2009. Novel hypoglycemic effects of Ganoderma lucidum water-extract in obese/diabetic (+db/+db) mice. Phytomedicine. 16(5):426–436.
   PubMed Web of Science ®Google Scholar
• Sheena N, Ajith TA, Janardhanan KK. 2003. Anti-inflammatory and anti-nociceptive activities of Ganoderma lucidum occurring in South India. Pharm Biol. 41(4):301–304.
   Web of Science ®Google Scholar
• Shiao MS. 2003. Natural products of the medicinal fungus Ganoderma lucidum: occurrence, biological activities, and pharmacological functions. Chem Rec. 3(3):172–180.
   PubMed Web of Science ®Google Scholar
• Taskinen M-R, Borén J. 2015. New insights into the pathophysiology of dyslipidemia in type 2 diabetes. Atherosclerosis. 239(2):483–495.
   PubMed Web of Science ®Google Scholar
• Teng BS, Wang CD, Yang HJ, Wu JS, Zhang D, Zheng M, Fan ZH, Pan D, Zhou P. 2011. A protein tyrosine phosphatase 1B activity inhibitor from the fruiting bodies of Ganoderma lucidum (Fr.) Karst and its hypoglycemic potency on streptozotocin-induced type 2 diabetic mice. J Agric Food Chem. 59(12):6492–6500.
   PubMed Web of Science ®Google Scholar
• Teng BS, Wang CD, Zhang D, Wu JS, Pan D, Pan LF, Yang HJ, Zhou P. 2012. Hypoglycemic effect and mechanism of a proteoglycan from Ganoderma lucidum on streptozotocin-induced type 2 diabetic rats. Eur Rev Med Pharmacol Sci. 16(2):166–175.
   PubMed Web of Science ®Google Scholar
• Tomlinson B, Hu M, Zhang Y, Chan P, Liu ZM. 2017. Evaluation of the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin for the treatment of type 2 diabetes. Expert Opin Drug Metab Toxicol. 13(2):211–223.
   PubMed Web of Science ®Google Scholar
• Ullah A, Khan A, Khan I. 2016. Diabetes mellitus and oxidative stress - a concise review. Saudi Pharm J. 24:547–553.
   PubMed Web of Science ®Google Scholar
• Upton R. 2000. American herbal pharmacopoeia and therapeutic compendium: Reishi mushroom, Ganoderma lucidum. Standards of analysis, quality control, and therapeutics. Scotts Valley (CA): American Herbal Pharmacopoeia.
   Google Scholar
• van der Hem LG, van der Vliet JA, Bocken CF, Kino K, Hoitsma AJ, Tax WJ. 1995. Ling Zhi-8: studies of a new immunomodulating agent. Transplantation. 60(5):438–443.
   PubMed Web of Science ®Google Scholar
• Vitak TY, Wasser SP, Nevo E, Sybirna NO. 2017. Enzymatic system of antioxidant protection of erythrocytes in diabetic rats treated with medicinal mushrooms Agaricus brasiliensis and Ganoderma lucidum (Agaricomycetes). Int J Med Mushrooms. 19(8):697–708.
   PubMed Web of Science ®Google Scholar
• Wachtel-Galor S, Szeto YT, Tomlinson B, Benzie IF. 2004a. Ganoderma lucidum ('Lingzhi'); acute and short-term biomarker response to supplementation. Int J Food Sci Nutr. 55(1):75–83.
   PubMed Web of Science ®Google Scholar
• Wachtel-Galor S, Tomlinson B, Benzie IF. 2004b. Ganoderma lucidum ("Lingzhi"), a Chinese medicinal mushroom: biomarker responses in a controlled human supplementation study. Ganoderma lucidum. 91:263–269.
   Google Scholar
• Wachtel-Galor S, Yuen J, Buswell JA, Benzie IFF. 2011. Chapter 9, Ganoderma lucidum (Lingzhi or Reishi): a medicinal mushroom. In: Benzie IFF, Wachtel-Galor S, editors. Herbal medicine: biomolecular and clinical aspects. 2nd ed. Boca Raton (FL): CRC Press/Taylor & Francis.
   Google Scholar
• Wang CW, Tschen JSM, Sheu WHH. 2008. Ganoderma lucidum on metabolic control in type 2 diabetes subjects - a double blinded placebo control study. J Intern Med. 19(1):54–60.
   Google Scholar
• Wang PC, Zhao S, Yang BY, Wang QH, Kuang HX. 2016. Anti-diabetic polysaccharides from natural sources: a review. Carbohydr Polym. 148:86–97.
   PubMed Web of Science ®Google Scholar
• Wanmuang H, Leopairut J, Kositchaiwat C, Wananukul W, Bunyaratvej S. 2007. Fatal fulminant hepatitis associated with Ganoderma lucidum (Lingzhi) mushroom powder. J Med Assoc Thai. 90(1):179–181.
   PubMedGoogle Scholar
• Wasser SP. 2010. Medicinal mushroom science: history, current status, future trends, and unsolved problems. Int J Med Mushr. 12(1):1–16.
   Web of Science ®Google Scholar
• Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, et al. 2018. 2018. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the american college of cardiology/american heart association task force on clinical practice guidelines. Circulation. 138(17):e484–e594.
   PubMed Web of Science ®Google Scholar
• Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, et al. 2018. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 39(33):3021–3104.
   PubMed Web of Science ®Google Scholar
• Winska K, Maczka W, Gabryelska K, Grabarczyk M. 2019. Mushrooms of the genus Ganoderma used to treat diabetes and insulin resistance. Molecules. 24(22):4075.
   PubMed Web of Science ®Google Scholar
• Witters LA. 2001. The blooming of the French lilac. J Clin Invest. 108(8):1105–1107.
   PubMed Web of Science ®Google Scholar
• World Health Organization. 2021. Cardiovascular diseases (CVDs). [accessed 2021 Jul 15]. Available from: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds).
   Google Scholar
• Wu Q, Li Y, Peng K, Wang XL, Ding Z, Liu L, Xu P, Liu GQ. 2019. Isolation and characterization of three antihypertension peptides from the mycelia of Ganoderma lucidum (Agaricomycetes). J Agric Food Chem. 67(29):8149–8159.
   PubMed Web of Science ®Google Scholar
• Wu Y, Wang D. 2009. A new class of natural glycopeptides with sugar moiety-dependent antioxidant activities derived from Ganoderma lucidum fruiting bodies. J Proteome Res. 8(2):436–442.
   PubMed Web of Science ®Google Scholar
• Xia Q, Zhang HZ, Sun XF, Zhao HJ, Wu LF, Zhu D, Yang GH, Shao YY, Zhang XX, Mao X, et al. 2014. A comprehensive review of the structure elucidation and biological activity of triterpenoids from Ganoderma spp. Molecules. 19(11):17478–17535.
   PubMed Web of Science ®Google Scholar
• Xiao C, Wu QP, Cai W, Tan JB, Yang XB, Zhang JM. 2012. Hypoglycemic effects of Ganoderma lucidum polysaccharides in type 2 diabetic mice. Arch Pharm Res. 35(10):1793–1801.
   PubMed Web of Science ®Google Scholar
• Xiao C, Wu Q, Xie Y, Tan J, Ding Y, Bai L. 2018. Hypoglycemic mechanisms of Ganoderma lucidum polysaccharides F31 in db/db mice via RNA-seq and iTRAQ. Food Funct. 9(12):6495–6507.
   PubMed Web of Science ®Google Scholar
• Xiao C, Wu Q, Zhang J, Xie Y, Cai W, Tan J. 2017. Antidiabetic activity of Ganoderma lucidum polysaccharides F31 down-regulated hepatic glucose regulatory enzymes in diabetic mice. J Ethnopharmacol. 196:47–57.
   PubMed Web of Science ®Google Scholar
• Xie YZ, Yang F, Tan W, Li X, Jiao C, Huang R, Yang BB. 2016. The anti-cancer components of Ganoderma lucidum possesses cardiovascular protective effect by regulating circular RNA expression. Oncoscience. 3(7–8):203–207.
   PubMedGoogle Scholar
• Xu Z, Chen X, Zhong Z, Chen L, Wang Y. 2011. Ganoderma lucidum polysaccharides: Immunomodulation and potential anti-tumor activities. Am J Chin Med. 39(1):15–27.
   PubMed Web of Science ®Google Scholar
• Xu J, Xiao C, Xu H, Yang S, Chen Z, Wang H, Zheng B, Mao B, Wu X. 2021. Anti-inflammatory effects of Ganoderma lucidum sterols via attenuation of the p38 MAPK and NF-κB pathways in LPS-induced RAW 264.7 macrophages. Food Chem Toxicol. 150:112073.
   PubMed Web of Science ®Google Scholar
• Yang Z, Chen C, Zhao J, Xu W, He Y, Yang H, Zhou P. 2018a. Hypoglycemic mechanism of a novel proteoglycan, extracted from Ganoderma lucidum, in hepatocytes. Eur J Pharmacol. 820:77–85.
   PubMed Web of Science ®Google Scholar
• Yang Z, Wu F, He Y, Zhang Q, Zhang Y, Zhou G, Yang H, Zhou P. 2018b. A novel PTP1B inhibitor extracted from Ganoderma lucidum ameliorates insulin resistance by regulating IRS1-GLUT4 cascades in the insulin signaling pathway. Food Funct. 9(1):397–406.
   PubMed Web of Science ®Google Scholar
• Yoon HM, Jang KJ, Han MS, Jeong JW, Kim GY, Lee JH, Choi YH. 2013. Ganoderma lucidum ethanol extract inhibits the inflammatory response by suppressing the NF-κB and toll-like receptor pathways in lipopolysaccharide-stimulated BV2 microglial cells. Exp Ther Med. 5(3):957–963.
   PubMed Web of Science ®Google Scholar
• Yuen MF, Ip P, Ng WK, Lai CL. 2004. Hepatotoxicity due to a formulation of Ganoderma lucidum (Lingzhi). J Hepatol. 41(4):686–687.
   PubMed Web of Science ®Google Scholar
• Yurkiv B, Wasser SP, Nevo E, Sybirna NO. 2015. Antioxidant effects of medicinal mushrooms Agaricus brasiliensis and Ganoderma lucidum (higher Basidiomycetes): evidence from animal studies. Int J Med Mushrooms. 17(10):943–955.
   PubMed Web of Science ®Google Scholar
• Zeng P, Guo Z, Zeng X, Hao C, Zhang Y, Zhang M, Liu Y, Li H, Li J, Zhang L. 2018. Chemical, biochemical, preclinical and clinical studies of Ganoderma lucidum polysaccharide as an approved drug for treating myopathy and other diseases in China. J Cell Mol Med. 22(7):3278–3297.
   PubMed Web of Science ®Google Scholar
• Zhang HN, He JH, Yuan L, Lin ZB. 2003. In vitro and in vivo protective effect of Ganoderma lucidum polysaccharides on alloxan-induced pancreatic islets damage. Life Sci. 73(18):2307–2319.
   PubMed Web of Science ®Google Scholar
• Zhang HN, Lin ZB. 2004. Hypoglycemic effect of Ganoderma lucidum polysaccharides. Acta Pharmacol Sin. 25(2):191–195.
   PubMed Web of Science ®Google Scholar
• Zhang S, Pang G, Chen C, Qin J, Yu H, Liu Y, Zhang X, Song Z, Zhao J, Wang F, et al. 2019. Effective cancer immunotherapy by Ganoderma lucidum polysaccharide-gold nanocomposites through dendritic cell activation and memory T cell response. Carbohydr Polym. 205:192–202.
   PubMed Web of Science ®Google Scholar
• Zheng J, Yang B, Yu Y, Chen Q, Huang T, Li D. 2012. Ganoderma lucidum polysaccharides exert anti-hyperglycemic effect on streptozotocin-induced diabetic rats through affecting β-cells. Comb Chem High Throughput Screen. 15(7):542–550.
   PubMed Web of Science ®Google Scholar